The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...

2022 was an eventful year on the 340B front, packed with updates to consequential litigation, proposed new rules, ongoing uncertainty into the Health Resources and Services Administration's (HRSA) ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

Facilities and programs known as 340B-eligible "covered entities" routinely provide prescription drugs regardless of a patient's ability to pay. However, drugs purchased at 340B prices can be ...

HRSA is piloting a back-end rebate model despite CEs and numerous trade associations having raised significant legal, administrative and financial concerns with shifting a discount program to a rebate ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

WASHINGTON--(BUSINESS WIRE)--BIO President and CEO Jim Greenwood issued the following statement today regarding the introduction by Senator Charles Grassley of S. 2453, the Ensuring the Value of the ...